Expression of CXCR4 and Breast Cancer Prognosis: a Systematic Review and Meta-analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2014 Jan 31

PMID 24475985

Citations 71

Authors

Zhigang Zhang

Chao Ni

Wuzhen Chen

Ping Wu

Zhen Wang

Junhua Yin

Jian Huang

Fuming Qiu

Affiliations

Soon will be listed here.

Abstract

Background: The chemokine receptor CXCR4 plays a significant role in biological processes, as well as in tumorigenesis and the progression of cancer, especially breast cancer. However, the clinical application of CXCR4 for breast cancer prognosis is still very limited. A meta-analysis based on published studies was performed with the aim of obtaining an accurate evaluation of the relationship between CXCR4 expression and the prognosis of breast cancer.

Methods: A comprehensive search strategy was used to search relevant literature in PubMed, MEDLINE and the ISI Web of Science. The correlation between CXCR4 expression and clinicopathological features and breast cancer prognosis was analyzed. This meta-analysis was carried out using Review Manager 4.2.

Result: Thirteen eligible studies consisting of 3865 participants were included. We found that breast cancers with CXCR4 expression were associated with lymph node status (pooled RR =1.20, 95% CI: 1.01-1.43, P<0.001) and distant metastasis (pooled RR =1.52, 95% CI: 1.17-1.98, P = 0.125). CXCR4 overexpression was significantly associated with disease free survival (DFS) (RR = 0.77, 95% CI = 0.70-0.86, P = 0.554) and overall survival (OS) (RR = 0.70, 95% CI = 0.59-0.83, P = 0.329). However, there was no significant association between CXCR4 expression and some clinical parameters of breast cancer, such as tumor category, ER status, PR status, or c-erbB-2 status.

Conclusion: Our meta-analysis showed that CXCR4 is an efficient prognostic factor for breast cancer. Overexpression of CXCR4 was significantly associated with lymph node status and distant metastasis and indicated poor overall and disease free survival.

Citing Articles

Subverting to Prevent : Alteration of Effector Immune Cell Migration and Adhesion as a Key Mechanism of Tumor Immune Evasion.

Mastrogiovanni M, Donnadieu E, Pathak R, Di Bartolo V Biology (Basel). 2024; 13(11).

PMID: 39596815 PMC: 11591779. DOI: 10.3390/biology13110860.

New Emerging Chemokine Receptors: CCR5 or CXCR5 on Tumor Is Associated with Poor Response to Chemotherapy and Poor Prognosis in Locally Advanced Triple-Negative Breast Cancer.

Cabioglu N, Onder S, Karatay H, Bayram A, Oner G, Tukenmez M Cancers (Basel). 2024; 16(13).

PMID: 39001456 PMC: 11240792. DOI: 10.3390/cancers16132388.

Unraveling malignant phenotype of peritumoral tissue: transcriptomic insights into early-stage breast cancer.

Morla-Barcelo P, Laguna-Macarrilla D, Cordoba O, Matheu G, Oliver J, Roca P Breast Cancer Res. 2024; 26(1):89.

PMID: 38831458 PMC: 11145834. DOI: 10.1186/s13058-024-01837-2.

Guerrache A, Micheau O Cells. 2024; 13(6.

PMID: 38534365 PMC: 10968836. DOI: 10.3390/cells13060521.

Inhibition of Dipeptidyl Peptidase-4 Activates Autophagy to Promote Survival of Breast Cancer Cells via the mTOR/HIF-1α Pathway.

Kawakita E, Yang F, Shi S, Takagaki Y, Koya D, Kanasaki K Cancers (Basel). 2023; 15(18).

PMID: 37760498 PMC: 10526496. DOI: 10.3390/cancers15184529.

References

Hiller D, Meschonat C, Kim R, Li B, Chu Q . Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer. Surgery. 2011; 150(3):459-65. DOI: 10.1016/j.surg.2011.07.005. View

Zlotnik A . New insights on the role of CXCR4 in cancer metastasis. J Pathol. 2008; 215(3):211-3. DOI: 10.1002/path.2350. View

Gil M, Seshadri M, Komorowski M, Abrams S, Kozbor D . Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S A. 2013; 110(14):E1291-300. PMC: 3619300. DOI: 10.1073/pnas.1220580110. View

Burger J, Kipps T . CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2005; 107(5):1761-7. DOI: 10.1182/blood-2005-08-3182. View

Chu Q, Holm N, Madumere P, Johnson L, Abreo F, Li B . Chemokine receptor CXCR4 overexpression predicts recurrence for hormone receptor-positive, node-negative breast cancer patients. Surgery. 2010; 149(2):193-9. DOI: 10.1016/j.surg.2010.05.016. View

Holm N, Byrnes K, Li B, Turnage R, Abreo F, Mathis J . Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res. 2007; 141(1):53-9. DOI: 10.1016/j.jss.2007.03.015. View

Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J . CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010; 29(4):709-22. PMC: 3175097. DOI: 10.1007/s10555-010-9256-x. View

Mukherjee D, Zhao J . The Role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res. 2013; 3(1):46-57. PMC: 3555200. View

Woo S, Bae J, Kim C, Lee J, Koo B . A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer. Ann Surg Oncol. 2007; 15(1):281-5. DOI: 10.1245/s10434-007-9595-1. View

10.

Teicher B, Fricker S . CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010; 16(11):2927-31. DOI: 10.1158/1078-0432.CCR-09-2329. View

11.

Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A . Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005; 23(7):879-94. DOI: 10.1634/stemcells.2004-0342. View

12.

Liang Z, Yoon Y, Votaw J, Goodman M, Williams L, Shim H . Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005; 65(3):967-71. PMC: 3734941. View

13.

Liu Y, Ji R, Li J, Gu Q, Zhao X, Sun T . Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J Exp Clin Cancer Res. 2010; 29:16. PMC: 2845107. DOI: 10.1186/1756-9966-29-16. View

14.

Su Y, Wu M, Huang C, Hou M, Yang S, Chai C . Expression of CXCR4 is associated with axillary lymph node status in patients with early breast cancer. Breast. 2005; 15(4):533-9. DOI: 10.1016/j.breast.2005.08.034. View

15.

He H, Wang C, Shen Z, Fang Y, Wang X, Chen W . Upregulated expression of C-X-C chemokine receptor 4 is an independent prognostic predictor for patients with gastric cancer. PLoS One. 2013; 8(8):e71864. PMC: 3735563. DOI: 10.1371/journal.pone.0071864. View

16.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100. PMC: 2707010. DOI: 10.1371/journal.pmed.1000100. View

17.

Wendel C, Hemping-Bovenkerk A, Krasnyanska J, Mees S, Kochetkova M, Stoeppeler S . CXCR4/CXCL12 participate in extravasation of metastasizing breast cancer cells within the liver in a rat model. PLoS One. 2012; 7(1):e30046. PMC: 3258260. DOI: 10.1371/journal.pone.0030046. View

18.

Busillo J, Benovic J . Regulation of CXCR4 signaling. Biochim Biophys Acta. 2006; 1768(4):952-63. PMC: 1952230. DOI: 10.1016/j.bbamem.2006.11.002. View

19.

Luker K, Luker G . Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 2005; 238(1):30-41. DOI: 10.1016/j.canlet.2005.06.021. View

20.

Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R . The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat. 2005; 97(3):275-83. DOI: 10.1007/s10549-005-9121-8. View